Twin Tree Management
VRTX icon

Twin Tree Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Twin Tree Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$12M Buy
26,800
+1,400
+6% +$653K 0.25% 64
2025
Q4 		$11.5M Sell
25,400
-21,200
-45% -$9.14M 0.1% 252
2025
Q3 		$18.3M Buy
46,600
+12,500
+37% +$5.22M 0.08% 314
2025
Q2 		$15.2M Sell
34,100
-10,000
-23% -$4.61M 0.03% 588
2025
Q1 		$21.4M Buy
44,100
+38,800
+732% +$18.1M 0.04% 409
2024
Q4 		$2.13M Buy
+5,300
New +$2.46M ﹤0.01% 1132
2024
Q2 		– Sell
-122,200
Closed -$51.1M – 1680
2024
Q1 		$51.1M Sell
122,200
-60,200
-33% -$25.4M 0.11% 175
2023
Q4 		$74.2M Buy
+182,400
New +$67.4M 0.14% 135
2023
Q1 		– Sell
-47,300
Closed -$13.7M – 1613
2022
Q4 		$13.7M Sell
47,300
-100
-0.2% -$30.5K 0.03% 488
2022
Q3 		$13.7M Sell
47,400
-7,400
-14% -$2.13M 0.03% 473
2022
Q2 		$15.4M Buy
54,800
+5,400
+11% +$1.45M 0.02% 502
2022
Q1 		$12.9M Sell
49,400
-20,100
-29% -$4.77M 0.02% 622
2021
Q4 		$15.3M Buy
+69,500
New +$13.5M 0.03% 496
2020
Q1 		– Sell
-4,300
Closed -$941K – 1642
2019
Q4 		$941K Buy
+4,300
New +$870K ﹤0.01% 872
2019
Q2 		– Sell
-3,500
Closed -$644K – 1576
2019
Q1 		$644K Buy
+3,500
New +$646K ﹤0.01% 915
2018
Q4 		– Sell
-19,000
Closed -$3.66M – 1528
2018
Q3 		$3.66M Buy
+19,000
New +$3.38M 0.02% 459
2018
Q1 		– Sell
-101,600
Closed -$15.2M – 1324
2017
Q4 		$15.2M Sell
101,600
-56,000
-36% -$8.29M 0.11% 151
2017
Q3 		$24M Buy
+157,600
New +$23.7M 0.19% 107

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Twin Tree Management's VRTX Position: Q1 2026 in Review

Twin Tree Management opened a new position in Vertex Pharmaceuticals (VRTX) in Q1 2026: 7,769 shares worth $3.47M. The stake represents 0.07% of the portfolio and ranks #309 among its holdings. This is a return to the name: Twin Tree Management previously reported a position in VRTX as recently as Q1 2025.

Twin Tree Management first reported a position in VRTX in Q3 2017 and has held it in 26 quarters since. The position peaked at $52.8M in Q4 2023. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Twin Tree Management held 7,769 shares of Vertex Pharmaceuticals worth $3.47M as of Q1 2026.
  • Vertex Pharmaceuticals was a new Twin Tree Management position in Q1 2026.
  • Vertex Pharmaceuticals made up 0.07% of Twin Tree Management's portfolio in Q1 2026, its #309 holding.
  • Twin Tree Management first reported a position in Vertex Pharmaceuticals in Q3 2017 and has held it in 26 quarters since.
  • Twin Tree Management's Vertex Pharmaceuticals position peaked at $52.8M in Q4 2023.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Twin Tree Management's 13F filing for Q1 2026, filed 14 May 2026.